0001209191-19-024102.txt : 20190409
0001209191-19-024102.hdr.sgml : 20190409
20190409165006
ACCESSION NUMBER: 0001209191-19-024102
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190405
FILED AS OF DATE: 20190409
DATE AS OF CHANGE: 20190409
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gregory Philip D
CENTRAL INDEX KEY: 0001343543
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35966
FILM NUMBER: 19739923
MAIL ADDRESS:
STREET 1: POINT RICHMOND TECH CENTER II
STREET 2: 501 CANAL BOULEVARD SUITE A100
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: bluebird bio, Inc.
CENTRAL INDEX KEY: 0001293971
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 339-499-9300
MAIL ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc
DATE OF NAME CHANGE: 20040616
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-04-05
0
0001293971
bluebird bio, Inc.
BLUE
0001343543
Gregory Philip D
C/O BLUEBIRD BIO, INC.
60 BINNEY STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Scientific Officer
Common Stock
2019-04-05
4
M
0
600
50.51
A
33192
D
Common Stock
2019-04-05
4
M
0
700
75.60
A
33892
D
Common Stock
2019-04-05
4
S
0
800
156.3325
D
33092
D
Common Stock
2019-04-05
4
S
0
300
157.9067
D
32792
D
Common Stock
2019-04-05
4
S
0
700
158.9186
D
32092
D
Stock Option (right to buy)
50.51
2019-04-05
4
M
0
600
0.00
D
2026-03-01
Common Stock
600
11600
D
Stock Option (right to buy)
75.60
2019-04-05
4
M
0
700
0.00
D
2027-02-01
Common Stock
700
27800
D
The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on July 2, 2018.
The range in prices for the transaction reported on this line was $156.01 to $156.65. The average weighted price was $156.3325. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range in prices for the transaction reported on this line was $157.76 to $157.98. The average weighted price was $157.9067. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range in prices for the transaction reported on this line was $158.64 to $159.38. The average weighted price was $158.9186. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter.
This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2018 and in 36 equal monthly installments thereafter.
/s/ Jason F. Cole, Attorney-in-Fact
2019-04-09